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Abstract
Background: Protein-protein interaction (PPI) data sets generated by high-throughput
experiments are contaminated by large numbers of erroneous PPIs. Therefore, computational
methods for PPI validation are necessary to improve the quality of such data sets. Against the
background of the theory that most extant PPIs arose as a consequence of gene duplication, the
sensitive search for homologous PPIs, i.e. for PPIs descending from a common ancestral PPI, should
be a successful strategy for PPI validation.
Results: To validate an experimentally observed PPI, we combine FASTA and PSI-BLAST to
perform a sensitive sequence-based search for pairs of interacting homologous proteins within a
large, integrated PPI database. A novel scoring scheme that incorporates both quality and quantity
of all observed matches allows us (1) to consider also tentative paralogs and orthologs in this
analysis and (2) to combine search results from more than one homology detection method. ROC
curves illustrate the high efficacy of this approach and its improvement over other homology-based
validation methods.
Conclusion: New PPIs are primarily derived from preexisting PPIs and not invented de novo. Thus,
the hallmark of true PPIs is the existence of homologous PPIs. The sensitive search for homologous
PPIs within a large body of known PPIs is an efficient strategy to separate biologically relevant PPIs
from the many spurious PPIs reported by high-throughput experiments.
Background
Physical interactions between proteins, commonly
referred to as protein-protein interactions (PPIs), occur at
every level of cell function to elaborate the organism's
phenotype. The study of PPIs is therefore of great interest
and is helping to reveal basic molecular mechanisms of
many diseases. High-throughput screening methods have
given insight into hundreds of thousands of potential
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of high-throughput approaches is their high rate of false-
positive PPIs, i.e. erroneously reported PPIs that do not
occur in vivo [1-7].
The development and implementation of computational
methods for the validation of experimentally determined
PPIs is therefore an important goal in bioinformatics
today. Common approaches include determining inter-
sections between different high-throughput PPI data sets
[3], incorporating protein annotation data [5,8], analyz-
ing expression profiles [4,9-12], investigating topological
criteria of PPI networks [13-17], and inspecting patterns
of co-evolution [18].
Another, well established in silico technique to validate an
experimentally determined PPI is to check if homologs of
the interacting proteins also interact; if so, the confidence
of this PPI is increased. The original interolog concept sug-
gests to examine PPIs among functionally conserved
orthologs, i.e. functionally conserved proteins in other spe-
cies that evolved from a common ancestor [19,20]. How-
ever, large-scale application of this method for PPI
validation is strongly hampered by limited coverage of
most interactomes and by low numbers of known bona
fide orthologs [21]. A first practical approach involved the
inspection of PPIs among paralogous proteins, i.e. homol-
ogous proteins that evolved by gene duplication and are
found within the same species [4]. Nevertheless, sensitiv-
ity remains a problem because in most organisms assured
paralogs with known interactions are scarce. The strategy
illustrated in Figure 1, which is followed in this paper,
searches for homologous PPIs independent of species
boundaries or functional constraints, which significantly
increases the amount of PPI data usable for validation
purposes (if not stated otherwise, the term 'homologous
PPI' is understood as defined in Figure 1). Several papers
applied this 'all-inclusive' approach to homology-based
PPI validation [8,22,23]. Also techniques developed for
PPI prediction, a relatively more well-studied bioinfor-
matics problem, successfully utilized this idea, for exam-
ple Brown et al. [24] or Jonsson et al. [25]. However, the
focus of the present paper is not PPI prediction but the
computational validation of experimentally determined
PPIs.
Firstly, we draw the reader's attention to the duplication-
divergence hypothesis of PPI evolution, i.e. the idea that
extant PPIs primarily originate from gene duplications,
the homologs diverging over time. If PPIs share common
evolutionary ancestry, which is what this hypothesis sug-
gests, then this ancestry reaches far into the evolutionary
past. Consequently, homology-based PPI validation
should investigate also diverged homologs and not only
similar proteins.
Secondly, motivated by this idea, we propose an
improved, sequence-based procedure for homology-
based PPI validation. Unlike previously published, mostly
binary validation schemes that deem a questioned PPI as
biologically relevant as soon as a single homologous PPI
is found, we follow a similar approach as Jonsson et al.
[25] and compute a confidence score that takes into
account both the quality and quantity of all identified
homologous PPIs. The assignment of higher scores to
high-quality hits and of lower scores to low-quality hits
allows us to extend the search for homologous PPIs from
reliable homologs to highly putative paralogs and
orthologs with E-values up to 10. In addition to similar
scoring schemes proposed before, we normalize and com-
bine scores obtained from different homology search
strategies.
Thirdly, we demonstrate the high efficacy of homology-
based validation when carried out on large PPI data sets.
A comprehensive data set of known physical binary PPIs
from six PPI source databases is compiled, comprising
135,276 PPIs from 20 different organisms. This is, to the
best of our knowledge, the largest collection of PPIs that
has been used so far in this kind of analysis. Based on
Receiver Operating Characteristic (ROC) curves it is
shown that the new approach improves over previous
methods for homology-based PPI validation.
Results and discussion
Duplication-Divergence Hypothesis of PPI Evolution
Gene duplication is a ubiquitous mechanism in molecu-
lar evolution and the principal source of biological inno-
vation, producing new proteins and novel functional
domains [26-30]. Here, we follow the idea that the dupli-
cation of genetic material coupled with subsequent diver-
gence is also the dominant mechanism for the
development of novel PPIs [31]. This hypothesis is sup-
ported by both theoretical models [32-34] and empirical
evidence [35-40]. A brief review of papers supporting the
duplication-divergence hypothesis can be found in Addi-
tional file 1.
Duplication-divergence models of PPI evolution propose
a simple and yet plausible idea of how evolution might
have formed PPI networks over millions of years – by
repeated duplication of interacting genes followed by
their divergence. Figure 2 illustrates this idea.
Implications of the Duplication-Divergence Model for 
Homology-Based PPI Validation
The duplication-divergence model of PPI evolution as
shown in Figure 2 suggests that most biologically relevant
PPIs descend from a common ancestral PPI, i.e. the PPIs
are homologous to each other. This allows assessing the
plausibility of an experimentally determined PPI as fol-Page 2 of 13
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Homology-Based PPI ValidationFigure 1
Homology-Based PPI Validation. Concept of homology-based PPI validation: based on an experimentally observed physi-
cal interaction between two proteins, X and Y (the questioned 'source' PPI), homologs of both proteins are identified, for 
example by local sequence alignments. These homologs include both paralogs from within the same species and orthologs from 
other species. An interaction between a homolog of X and a homolog of Y is called a 'homologous PPI'. If an experimentally 
observed homologous PPI is found (thick lines), confidence in the questioned source PPI increases.
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Duplication-Divergence Model of PPI EvolutionFigure 2
Duplication-Divergence Model of PPI Evolution. Simplified gene tree illustrating the emergence of new PPIs under the 
duplication-divergence model of PPI evolution. In an ancestral species, the gene encoding a self-interacting protein, A, is dupli-
cated. From the resulting genes A1 and A2, A1 at some point loses its capability for self-interaction. Subsequent speciation forms 
the rat (R) and mouse (M) lineages, which evolve differently: in the mouse lineage, gene M1 is duplicated again, in the rat lineage 
R2 is duplicated. One of the R2 duplicates loses its capability for homodimerization due to deleterious mutations. Colors indi-
cate the two groups of orthologous genes. Note that all depicted PPIs are homologous in the narrow sense of the word, 
because they share a common ancestor.
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BMC Bioinformatics 2009, 10:21 http://www.biomedcentral.com/1471-2105/10/21lows: for a true-positive PPI, one expects to see many
homologous PPIs, whereas for a false-positive PPI this
should be less likely. A sensitive search for homologous
PPIs should thus, in principle, be able to filter out large
numbers of false-positive PPIs from experimental PPI data
sets while retaining the bulk of true-positive PPIs. How-
ever, both the incompleteness of today's PPI data sets and
the fact that common ancestry is often elusive represent
major practical obstacles along the way.
For assessing the validity of an experimentally predeter-
mined PPI, also 'weak' homologous PPIs can be informa-
tive ('weak' in the sense of 'weak signal of homology').
Their incidence might support or contradict the idea that
a questioned PPI evolved by duplication-divergence,
which in turn can strengthen or weaken the position that
a PPI is biologically relevant. However, the value of weak
homologous PPIs for PPI prediction is limited: one cannot
infer from a given pair of interacting proteins that very dis-
tant homologs interact as well. In the majority of cases
this prediction would be simply wrong, because due to
divergence most duplicated PPIs are eventually lost. PPIs
inferred by homology are thus only trustworthy if protein
similarity is high [41,42] or if these PPIs are supported by
complementary data [24].
Weak Homologous Interactions – Signal or Noise?
If the duplication-divergence model of PPI evolution is
correct, the existence of weak homologous PPIs should be
an observable characteristic of biologically relevant PPIs.
We set out to test this hypothesis. For both Gold Standard
Positive (GSP) and Gold Standard Negative (GSN) data
sets, PSI-BLAST was used to search for homologous PPIs,
and their distribution was determined within different E-
value windows. Figure 3 shows the results. It reveals two
important differences between GSP PPIs and GSN PPIs.
Firstly, there is an increased probability for GSP PPIs to
have at least one paralogous or orthologous PPI. Sec-
ondly, significantly more GSP PPIs than GSN PPIs have
large numbers of paralogous and orthologous PPIs (>10).
Most interestingly, both differences are observed up to
high E-value windows.
Not surprisingly, the first characteristic, the existence of at
least one homologous PPI, is a highly reliable signal for
GSP PPIs when sequence similarity is high. For example,
almost every fifth PPI taken out of the GSP data set (18%)
has a homologous PPI with an E-value lower than 10-100
(Figure 3A). By contrast, the existence of such high-quality
homologs is extremely unlikely for a GSN PPI (0.25%).
The signal remains intact with very low levels of sequence
similarity: within the last E-value window (ranging from
3 to 10) the probability of observing a homologous PPI
for a GSP PPI remains still twice as high (63%) as for a
GSN PPI (30%).
The distribution of homologous PPIs reveals the second
interesting characteristic of GSP PPIs: they tend to accu-
mulate large numbers of homologous PPIs. According to
Figure 3A, in all windows with E-values greater than 10-20,
about 25% of GSP PPIs have more than 10 homologous
PPIs; for GSN PPIs, this percentage never exceeds 8%.
Thus, for many PPIs the existence of a large number of
homologous PPIs is more conclusive than the existence of
at least one homologous PPI, especially when sequence
similarity is low: whereas about twice as many GSP PPIs
than GSN PPIs have at least one homologous PPI within
the last E-value window, almost four times as many GSP
PPIs (21.4%) than GSN PPIs (5.8%) have between 10 and
100 homologs, and more than five times as many GSP
PPIs (6.8%) than GSN PPIs (1.3%) have more than 100
homologs.
Both characteristics are observed independently of the fact
whether only paralogous (Figure 3B) or only orthologous
PPIs (Figure 3C) are investigated. For lower numbers of
homologous PPIs, stronger signals on the paralogous data
set are obtained than on the orthologous data set, which
is consistent with the finding that PPIs seem to be more
conserved within species than across species [41]. Interest-
ingly, very large numbers (>100) of homologous PPIs are
observed within the orthologous data set, most likely due
to an increased number of gene duplications in higher
eukaryotes.
We conclude that weak homologous PPIs are indeed an
observable and distinguishing characteristic of biologi-
cally relevant PPIs, especially if they are observed in
increased numbers. Consequently, weak homologous
PPIs should be considered by homology-based PPI valida-
tion schemes.
Overall Performance
We devised a scoring scheme that incorporates the find-
ings from Figure 3 (see Methods). The Receiver Operating
Characteristic (ROC) curves in Figure 4 illustrate the over-
all performance of this scoring scheme for the MIPS, the
Small Scale and the Multiple Evidence gold standard data
sets. The y-axis shows the True-Positive Rate (TPR or sensi-
tivity), i.e. the percentage of GSP PPIs that were correctly
confirmed as biologically relevant. The x-axis represents
the False-Positive Rate (FPR or 1-specificity), i.e. the per-
centage of GSN PPIs that were erroneously confirmed as
biologically relevant. By varying the threshold of the score
above which a PPI is confirmed as biologically relevant,
different FPRs and TPRs are observed (a short introduc-
tion to ROC curves can be found in Additional file 1). For
example, on the MIPS and the Multiple Evidence data sets,
a TPR of more than 70% at an FPR of 10% is observed. An
increased threshold results in a TPR of 80% at an FPR of
20% for the same two data sets. These values comparePage 5 of 13
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Number of Homologous PPIsFigur  3
Number of Homologous PPIs. Percentage of GSP PPIs (Combined data set, left bars) and GSN PPIs (Random data set, right 
bars) with a certain number of homologous PPIs (A), paralogous PPIs (B), and orthologous PPIs (C). We investigated eight dis-
tinct E-value windows (x-axis) and used PSI-BLAST to determine the number of homologous PPIs within each of these win-
dows (y-axis, numbers not cumulative). Each bar is composed of four distinct groups: the percentage of PPIs with a single 
identified homologous PPI, the percentage with 2 to 10 homologous PPIs, the percentage with 11 to 100 homologous PPIs, and 
the percentage with more than 100 identified homologous PPIs.
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(B) Identified Paralogous PPIs for GSP and GSN PPIs
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(C) Identified Orthologous PPIs for GSP and GSN PPIs
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based PPI validation techniques [11-14,18]. This under-
scores the high efficacy of homology-based PPI valida-
tion, especially when carried out on rich PPI data sets.
The Small Scale gold standard performs worst, which
might reflect differences in the quality of the data sets. The
Multiple Evidence gold standard can be considered of high-
est quality, because detection of a PPI with different exper-
imental methods is a very reliable indicator of its existence
[3]. Indeed, this data set achieves the best performance up
to a TPR of 70%. The MIPS gold standard contains PPIs
audited by human experts and is thus very trustworthy as
well, although a slightly poorer performance is seen on
this data set. PPIs of the Small Scale gold standard are not
reviewed manually and thus its reliability might to a large
degree reflect the quality of the automated text mining
tools that are frequently used to extract them from the sci-
entific literature. Because these tools are error-prone [43],
the Small Scale gold standard might contain more spuri-
ous PPIs than the other two data sets.
Note that although the class distribution in the gold
standard data sets is skewed, i.e. the Random GSN data set
is about 50 times larger than each GSP data set, this does
not affect the overall ROC curve [44]. In fact, we observed
the same overall ROC curve on a balanced data set where
the number of randomly chosen GSNs roughly equals the
number of GSPs (data not shown). ROC curves as shown
in Figure 4 are ideal to illustrate the overall performance
of a classifier, but do not make suggestions about which
specific score threshold should be applied to classify a PPI
as true or false. This decision depends on the TPR and FPR
one is willing to accept. Supplementary Figure 1 shows
selected score thresholds and their associated TPRs and
FPRs.
Comparison of Homology-Based Validation Schemes
Previous homology-based PPI validation methods
involve simpler, binary selection processes in which a PPI
is deemed to be biologically relevant as soon as a single
homologous PPI is found [4,8,23]. Figure 5 shows a per-
formance comparison with two of these methods. Note
that this comparison does not include homology-based
PPI prediction techniques, although these techniques are
widely used. The reason is that these techniques have a
different focus and generally incorporate also non-homol-
ogy-based criteria, which makes a direct comparison diffi-
cult.
The FASTA-based binary validation scheme shows
remarkably high specificity, even at high E-values. For
example, inclusion of homologous PPIs with E-values
between 10-4 and 10 results in an increase of the TPR of
almost 25% (from 48.5% to 72.1%), whereas the FPR
grows only by 13.5% within the same interval, remaining
below 16%. Considering the low sequence similarity and
the probable existence of many spurious hits at E-values
up to 10, this find is remarkable. By contrast, the PSI-
BLAST-based binary validation scheme is less specific
(even at low E-values), but much more sensitive: almost
87% of the GSP PPIs have at least one homologous PPI
identified by PSI-BLAST (E-value ≤ 10). In addition to
FASTA and PSI-BLAST, also BLAST was evaluated for
homology detection (data not shown). In comparison to
FASTA, no noticeable difference in performance was
observed except for a slight decrease in maximum sensitiv-
ity (about 2% lower than with FASTA). Our scoring
scheme, represented by the blue curve (squares), com-
bines evidence from homologous PPIs found by FASTA
and PSI-BLAST and clearly outperforms both individual
binary validation schemes. For example, at a TPR of 70%
it produces 4% fewer false-positives than the FASTA-based
binary approach, and about 6% fewer false-positives than
the PSI-BLAST-based binary validation scheme.
Overall PerformanceFigure 4
Overall Performance. Overall performance of the scoring 
scheme on the MIPS, the Small Scale, and the Multiple Evidence 
gold standard data sets. The Random data set served as the 
gold standard negative. Each data point of the curves corre-
sponds to a pair of true-positive and false-positive rates, 
defined as the fraction of GSP PPIs and GSN PPIs that 
achieved a score above a sliding threshold. The threshold 
ranged from 1 to 10-5 in this figure (values not shown). The 
area under the curve (AUC) is 84%, 86%, and 87% for the 
Small Scale, the Multiple Evidence, and the MIPS curve, respec-
tively.
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different parameter settings. Saeed and Deane [23] used
BLAST with an E-value up to 10-4 to identify homologous
PPIs and evaluated a TPR of 63% at an FPR of 7%. If this
setting is transferred to FASTA and applied on our data
sets, a TPR of 48.5% at an FPR of 2.3% is observed. Our
scoring scheme, by contrast, produces only 1.5% false-
positives at the same level of sensitivity (48.5%). The dif-
ference in FPR increases for higher levels of sensitivity,
illustrating the additional value from incorporation of
multiple methods for homology detection and from con-
sideration of weak homologs. Patil and Nakamura [8]
used PSI-BLAST with an E-value up to 10-8 and reported a
TPR of 89.7% at an FPR of 37.1% for their gold standards.
On our data set the same parameter setting results in a sig-
nificantly worse TPR of 70.1% at an FPR of 16.1%. Again,
the scoring scheme outperforms and achieves a reduced
FPR of 10% at the same level of sensitivity (70.1%). It is
noteworthy that our exclusively sequence-based scoring
scheme produces a superior ROC curve than Patil and
Nakamura's Bayesian network approach, which incorpo-
rates three genomic features instead of one (sequence,
structure and annotation information). This underscores
again the potential efficacy of homology-based methods.
No published PSI-BLAST parameters were found in the
paper from Deane et al. [4], and thus the performance of
this method was not assessed.
Contribution of Weak Homologs
Is it actually beneficial to include homologous PPIs with
high E-values (>1) for PPI validation, i.e. do weak
homologs indeed contribute positively in terms of
increased sensitivity and/or increased specificity? To
answer this question, the classification performance of the
scoring scheme with and without the inclusion of weak
homologs was determined. Figure 6 shows the results.
The inclusion of weak homologous PPIs contributes pos-
itively to the overall classification performance. For exam-
ple, the restriction of the analysis to homologous PPIs
with an E-value below 10-10 results in a maximum TPR of
69% at an FPR of 14.5%. When homologs with E-values
up to 1 are considered, the same sensitivity is achieved at
a significantly reduced FPR of 10%. Another increase of
the E-value threshold up to 10 leads to a further reduction
of the FPR by 1%.
Note that a similar effect cannot be observed for the clas-
sic, binary validation schemes, where less stringent E-
value thresholds increase sensitivity but decrease specifi-
city (Figure 5). This emphasizes the value of the scoring
approach: it finds evidence for biologically relevant PPIs
among weaker homologs without the compromise of an
increased rate of false-positives.
Although the additional benefit resulting from the inclu-
sion of weak homologs with an E-value above 1 is rather
low on this data set, we expect it to increase for data sets
where high-quality homologs are not at hand. Yeast is
comparably well investigated, with approximately 50% of
its estimated 40,000 to 75,000 PPIs known [45]. As a con-
sequence, most of its biologically relevant PPIs have
homologous PPIs among high-quality paralogs, and
matches among weak homologs add little extra value to
the overall score. This situation is different from most
other organisms where interactome coverage is far below
50% and where weak paralogs and orthologs are often the
only possibility to validate a questioned PPI.
Conclusion
Knowledge of PPIs is key to understanding cell function.
Although experimental high-throughput PPI detection
techniques are now making it possible to catalogue all
Comparison of Homology-Based Validation SchemesFigure 5
Comparison of Homology-Based Validation 
Schemes. Performance of the scoring scheme ('PRIMOS 
Score') in comparison to two conventional approaches 
(named 'FASTA Binary' and 'PSI-BLAST Binary' here), where 
a PPI is deemed as biologically relevant as soon as a single 
homologous PPI is found below a certain E-value. GSP PPIs 
comprised all PPIs from the Combined data set, the Random 
data set was used for the GSN PPIs. For the two binary 
schemes, we used FASTA and PSI-BLAST, respectively, to 
identify homologous PPIs and calculated the TPRs and FPRs 
as the fraction of GSP PPIs and GSN PPIs that had at least 
one homologous PPI below a sliding E-value threshold, rang-
ing from 10-300 to 10 in this figure. Black rectangle: parameter 
settings from Saeed and Deane [23]. Black circle: parameter 
setting used by Patil and Nakamura [8]. The area under the 
curve (AUC) is 82%, 83%, and 86% for the FASTA, PSI-
BLAST, and PRIMOS curve, respectively.
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methods are a major obstacle to achieving this ambitious
goal. Computational methods that can efficiently separate
the PPI wheat from the chaff are therefore highly desira-
ble.
We think that recent insights into the evolution of PPIs, in
particular the duplication-divergence hypothesis, might
be crucial to this endeavor. Nature is a tinkerer, not an
inventor [46]. For PPIs this means that new PPIs are pri-
marily derived from preexisting PPIs rather than invented
de novo. Consequently, most true-positive PPIs must have
homologous PPIs, not only among highly similar pro-
teins, but also among distantly related proteins. This
important characteristic of biologically relevant PPIs
should, in principle, allow successful discrimination
between true and false PPIs.
In light of this consideration, homology-based validation
techniques seem promising, but have not gained much
attention so far. Literature searches revealed only five
papers that proposed a homology-based technique to val-
idate experimental PPIs on a large scale, only three of
which presented a critical performance assessment. Pre-
sumably this reflects the fact that homology-based valida-
tion requires having at hand a set of PPIs among
homologous proteins, when few such PPIs have been
known. However, with more and more PPIs now being
reported from high-throughput experiments, this limita-
tion is no longer factor.
In this paper, we assembled a large PPI data set to reassess
the performance of homology-based PPI validation. It was
shown that the classic, binary validation technique is effi-
cient on such data sets, but can be further improved by
using multiple methods for homology detection and
more remote homologs to complement close homologs.
We expect the findings to be most relevant in situations
where interactions among assured paralogs or orthologs
are not at hand and thus traditional homology-based val-
idation is not an option. Existing PPI databases could use
the proposed method to reduce their number of false-pos-
itives without losing too many true-positives, especially
within well explored model organisms. Other prospective
applications include the elucidation of physically interact-
ing proteins from known protein complexes, or the vali-
dation of in silico predicted PPIs in cases where homology
was not used as a criterion for prediction in advance. Pro-
spective improvements may involve more sophisticated
methods for homology detection (e.g. Profile-HMMs),
identification of PPI-mediating protein features (e.g.
interacting domains) prior to homology detection to
refine the selection of homologs, and an assessment of the
statistical significance (P-values) of computed scores to
obtain an intuitive measure of a PPI's validity.
Methods
Database Search for Homologous PPIs
The modular architecture of proteins implies that a pro-
tein has not just one distinct evolutionary trajectory, but
one for each biological feature it contains [47]. Since in
general PPI-mediating features (e.g. the domains) are
unknown, one cannot selectively examine only trajecto-
ries of relevance. One possibility is to examine evolution-
ary trajectories of all protein features, but this comes with
an increased risk of detecting PPIs that are not truly
homologous. Also, if one wishes to include weak paralogs
and orthologs in the analysis to capture gene duplication
events that happened long time ago, methods for homol-
ogy detection become inaccurate and produce spurious
hits – another source of false homologous PPIs. To maxi-
mize both sensitivity and specificity despite these difficul-
ties, we opt for a large-scale, sequence-based screening
procedure in combination with a scoring scheme. Given
Contribution of Weak HomologsFigu e 6
Contribution of Weak Homologs. Contribution of weak 
homologous PPIs to the overall classification performance of 
the scoring scheme. The gray ROC curve (squares) repre-
sents the original performance of the scoring scheme (con-
siders all homologous PPIs with an E-value up to 10). The red 
ROC curve (crosses) illustrates the performance of the scor-
ing scheme when only homologs with an E-value up to 1 are 
examined, and the blue curve (triangles) ignores all homologs 
with an E-value above 10-10. GSP PPIs were taken from the 
Combined data set, GSN PPIs comprised all PPIs from the 
Random data set. The area under the curve (AUC) is 80%, 
85% and 86% for E-values 10-10, 1, and 10, respectively.
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PSI-BLAST [49] are used to search for homologous PPIs.
FASTA supplies more reliable results for closely related
proteins, while PSI-BLAST is more sensitive for remote
relationships [50]. To further increase the sensitivity of the
method, local sequence similarities with E-values up to 10
are considered. This produces many spurious hits, and
thus traditional homology-based PPI validation tech-
niques that simply check for the existence of a single
homologous PPI become misleading (compare Figure 3).
We therefore follow a similar approach as Jonsson et al.
[25] and apply a scoring scheme that weighs each match
according to its sequence similarity: low E-values score
high, and high E-values score low. Thus high scores can
result from few high-quality hits but also from numerous
low-quality hits.
Homologous PPIs are searched within a subset of the Pro-
tein Interaction and Molecule Search (PRIMOS) database
http://primos.fh-hagenberg.at, release BETA-2.7/2007–04
[51]. This subset consists of 135,276 redundancy-
removed, physical binary PPIs between 42,288 proteins
from 20 organisms, imported from six primary PPI data-
bases [52-57] (see Additional file 1). We used both FASTA
(fasta34.exe, v3.4) and PSI-BLAST (blastpgp.exe, v2.2.16)
to determine homologs for all proteins of our gold stand-
ard data sets. The search space for homologous proteins
was restricted to the set of 42,288 proteins with known
PPIs. According to Figure 1, we considered a homologous
PPI as an interaction found between a pair of homologous
proteins. E-value thresholds for both programs were set to
10, the ktup parameter of FASTA was set to 1, and the
number of iterations for PSI-BLAST was set to 10. All other
program parameters were left default.
Gold Standard Data Sets
Four gold standard positive (GSP) data sets and one gold
standard negative (GSN) data set with PPIs from Saccharo-
myces cerevisiae are used for performance assessment. Yeast
is relatively well-studied, which allows being rather strin-
gent in the selection of the GSP data sets. In addition,
yeast has already been used numerous times in similar
studies, which eases the comparison with previous results.
The MIPS GSP data set comprises 1,541 physical binary
PPIs obtained from the Comprehensive Yeast Genome
Database (CYGD) [57]. This database is considered as a
high-quality resource for yeast PPIs and is frequently used
as a gold standard reference set. PPIs reported by high-
throughput experiments are excluded from this data set
(see Additional file 1). The Multiple Evidence GSP data set
consists of 393 PPIs reported by at least two experimental
methods and in at least two different publications. As an
additional criterion, only publications imported from one
PPI database are considered. For example, if a PPI is
reported from a publication contained in DIP and MINT,
it will be excluded from the data set. If DIP is the only
source database for this PPI, the PPI will be included. In
an integrated dataset compiled from multiple source data
sets this procedure reduces the risk that duplicate PPIs are
regarded as homologous. The Small Scale data set consists
of yeast PPIs reported by 'small-scale' experiments and
contains 902 PPIs. Only PPIs of publications with up to
three reported PPIs are considered. To minimize the risk
of duplicate PPIs, publications imported from more than
one primary PPI database are excluded (same procedure
as for the Multiple Evidence GSP). The three GSP data sets
overlap only to a low degree: just 8 PPIs are common to
all three data sets, 25 between MIPS and Small Scale, 86
between Small Scale and Multiple Evidence, and 10 between
MIPS and Multiple Evidence. The Combined GSP data set
contains all PPIs from the previous three GSP data sets
(2,723 PPIs in total).
The Random GSN PPI data set was generated by randomly
selecting 50,000 protein pairs out of 7,058 yeast proteins
(UniProt [58] release 10.0, downloaded on March 29,
2007) that were not found interacting within the PRIMOS
database. A randomly selected data set is not completely
free of real PPIs, but has no selection bias, for example
towards protein pairs with different molecular functions
[23]. The amount of real PPIs within such a randomly
selected GSN data set should be generally low at about
0.25% [59].
Scoring Scheme
The score S(a, b) of a queried interaction between two pro-
teins a and b is defined as
where O is the set of organisms with known experimental
PPIs in the PRIMOS database, Ha(o) and Hb(o) denote the
sets of proteins from organism o that are homologous to
protein a and b, respectively. If there is experimental evi-
dence for an interaction between homolog ha and
homolog hb in the PRIMOS database, a score proportional
to their sequence similarity is added to an overall sum.
Note that the computation of S(a, b) excludes homolo-
gous PPIs where the two proteins are from different organ-
isms. Homologous PPIs from the same organism with one
protein identical to one of the source PPI proteins are
allowed. In this case, the E-value of the identical protein is
assumed to be 0. Furthermore, if two identical homolo-
gous PPIs are found in an organism, i.e. two pairs
S
sim  sim  interacts with 
otherwise
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( ) ( )
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a b
h h h ha b a b
ha
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then only the homologous PPI with the lower E-value is
considered. The other PPI is ignored. The E-value of a
homologous PPI (ha, hb) is defined as max(evalue(ha),
evalue(hb)). The similarity measure sim(x) of a homolo-
gous protein x is defined as
where evalue(x) is the E-value of homolog x reported by
FASTA and PSI-BLAST, respectively (note that FASTA and
PSI-BLAST scores are computed independently, see
below). For each pair of interacting homologs, the scoring
scheme basically extracts the positive exponent of the two
reported E-values (-log10) and multiplies these exponents
to get a joint similarity measure proportional to the simi-
larity of both homologs. The total score is then the sum
over all pairs of interacting homologs. Since a maximum
E-value of 10 is allowed, division by 100 ensures that the
negative logarithm is positive over the full range of possi-
ble E-values. The logarithm of zero is undefined, so E-val-
ues of zero are assigned the negative logarithm of roughly
the smallest reported E-value greater than zero (10-300).
This scoring scheme is similar to those proposed by Jons-
son et al. [25], but uses more interpretable E-values
instead of bit scores and puts more weight on the individ-
ual similarities of the two proteins (product of logarithms
instead of logarithm of products). We found this weighing
scheme important for rewarding high-quality hits where
both homologs exhibit a high-degree of similarity, in
which case the PPI in question is almost always true [23].
In addition, the score is then normalized, so that individ-
ual scores from different search strategies can be com-
pared and combined.
where Smax(a, b) is defined as S(a, b) with all ha assumed as
interacting with all hb. This scales the score to values rang-
ing from 0 (minimum score) to 1 (maximum score).
Two normalized scores are computed independently, one
with the homologs identified by FASTA and one with the
homologs identified by PSI-BLAST. The final score is
defined as the arithmetic mean of both normalized scores:
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